PDGFRB and non-small cell lung carcinoma: However, bevacizumab was approved only for nonsquamous NSCLC.12 Nintedanib prolonged overall survival (OS) only in patients with ACC.13 Sorafenib improved only the progression‐free survival (PFS) of NSCLC patients,14 while sunitinib and pazopanib showed no clear efficacy.15, 16, 17 Anlotinib is a multitargeted TKI that inhibits VEGFR, PDGFR, FGFR, c‐Kit, and other kinases.18 The ALTER0303 trial, which was a randomized, open‐label, phase 3 trial (NCT02388919), reported the efficacy of anlotinib for the third‐ and further‐line treatment of advanced NSCLC.